



a

## Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
IB/0030	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	30/05/2023		SmPC and PL	
IAIN/0031	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	24/05/2023	n/a		

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



IB/0029/G	<p>This was an application for a group of variations.</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.c.2.c - Change in the specification parameters and/or limits of the immediate packaging of the AS - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.c.3.b - Change in test procedure for the immediate packaging of the AS - Other changes to a test procedure (including replacement or addition)</p> <p>B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method</p>	27/01/2023	n/a		

	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
IA/0028/G	This was an application for a group of variations.  B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	11/10/2022	n/a		
IA/0027	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	14/06/2022	n/a		
IB/0026	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	17/05/2022	26/04/2023	SmPC and PL	To update section 4.5 of the SmPC and section 2 of the PL to update the wording on the interaction between praziquantel and efavirenz in products containing efavirenz as a single agent or in fixed dose combinations, as published in the Report from the CMDh meeting held on 14-16 December 2021, EMA/CMDh/730726/2021.

R/0025	Renewal of the marketing authorisation.	24/03/2022	17/05/2022	SmPC, Annex II and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IB/0023/G	<p>This was an application for a group of variations.</p> <p>B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.c.z - Container closure system of the AS - Other variation</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p>	15/06/2021	n/a		

	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
IB/0024/G	This was an application for a group of variations.  B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation	25/05/2021	n/a		
IB/0022/G	This was an application for a group of variations.  C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	24/04/2021	17/05/2022	SmPC and PL	
IB/0021	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	19/01/2021	06/05/2021	SmPC, Annex II, Labelling and PL	

II/0019	B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF	03/12/2020	n/a		
IA/0020/G	This was an application for a group of variations.  B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	25/05/2020	n/a		
IA/0018	A.7 - Administrative change - Deletion of manufacturing sites	11/05/2020	06/05/2021	Annex II and PL	
IAIN/0017	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	10/04/2020	n/a		
IAIN/0016	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	16/03/2020	23/04/2020	SmPC	
IB/0015	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO	16/08/2019	23/04/2020	Annex II	

	new additional data is required to be submitted by the MAH				
IB/0013/G	This was an application for a group of variations.  A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF	06/07/2019	n/a		
IB/0012	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	13/06/2019	n/a		
IB/0014	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	16/05/2019	23/04/2020	SmPC	
IB/0008/G	This was an application for a group of variations.  B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.d - Change in the specification parameters	27/03/2019	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
IB/0011	B.II.z - Quality change - Finished product - Other variation	22/03/2019	n/a		
IAIN/0010	B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer	12/03/2019	n/a		
IB/0009/G	<p>This was an application for a group of variations.</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>	19/02/2019	28/03/2019	SmPC and PL	



IG/1029	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	18/12/2018	n/a		
IA/0006	B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	13/09/2018	n/a		
IB/0005/G	This was an application for a group of variations.  C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH  C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	14/06/2018	08/11/2018	SmPC, Labelling and PL	
IAIN/0004	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/02/2018	n/a		
IAIN/0003	B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP -	09/01/2018	08/11/2018	Annex II and PL	

	Including batch control/testing				
IA/0002/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>	09/01/2018	n/a		
IB/0001	B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	20/11/2017	08/11/2018	SmPC, Labelling and PL	